Article
Oncology
Shuying Sun, Austin Zane, Carolyn Fulton, Jasmine Philipoom
Summary: This study investigates hemimethylation in lung cancer for the first time, demonstrating the existence of hemimethylation in lung cells and its potential association with the development of normal and tumor cells. Hemimethylation patterns are diverse and comparable between normal and tumor cells, with identified genes showing differential hemimethylation that may impact gene expression and cell function in non-small cell lung cancer.
Review
Immunology
Shuo Yang, Yang Huang, Qi Zhao
Summary: Lung cancer is a common malignancy and non-small cell lung cancer (NSCLC) is the most common type. Epigenetic alterations such as DNA methylation, histone modifications, and noncoding RNA expression are suggested to drive NSCLC development. Inflammation-related tumorigenesis plays a vital role in cancer research, but the exact relationship between immune components and epigenetic changes in inflammation is not clear. The connection between epigenetic drivers, inflammation, and NSCLC needs further investigation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Stefania Nicola, Irene Ridolfi, Giovanni Rolla, Pierluigi Filosso, Roberto Giobbe, Monica Boita, Beatrice Culla, Caterina Bucca, Paolo Solidoro, Luisa Brussino
Summary: This study found significantly higher levels of Th1 and Th17-related cytokines in the exhaled breath condensate of patients with non-small cell lung cancer compared to healthy controls, while no significant differences were observed for Th2-related cytokines. Significant correlations were found between FeNO levels and Th17-related cytokines, suggesting that IL-17 may indirectly contribute to increased lung production of nitric oxide in patients with NSCLC.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Yuqiu Hao, Hongna Dong, Wei Li, Xuejiao Lv, Bingqing Shi, Peng Gao
Summary: This study explores the role of IL-35 in the pathogenesis of non-small cell lung cancer (NSCLC) and provides new insights into its therapeutic potential.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Fen-Sheng Qiu, Jia-Qi He, Yu-Sen Zhong, Mei-Ying Guo, Chen-Huan Yu
Summary: This article explores the role of m6A modification in non-small cell lung cancer (NSCLC) and the impact of lung microbiota on it. m6A modification is considered as a novel biomarker and target for predicting the prognosis and chemotherapy sensitivity of lung cancer patients. Despite the emergence of many novel m6A-related inhibitors, their effectiveness and toxicity in NSCLC still need further investigation.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Letter
Medicine, General & Internal
Hollis Viray, Deepa Rangachari, Daniel B. Costa
Summary: The study reported initial data of trastuzumab deruxtecan in the treatment of lung cancers with ERBB2 mutations, including patients who had previously received ineffective ERBB2 tyrosine kinase inhibitors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Lin Zhou, Xiaomu Wang, Jingya Lu, Xiangning Fu, Yangkai Li
Summary: In this study, we found that UTX expression is significantly upregulated in cancer tissues of NSCLC patients, positively correlated with EGFR phosphorylation levels. UTX promotes proliferation and migration in NSCLC cell lines, and is closely associated with the EGFR signaling pathway.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Florian Janke, Arlou Kristina Angeles, Anja Lisa Riediger, Simone Bauer, Martin Reck, Albrecht Stenzinger, Marc A. Schneider, Thomas Muley, Michael Thomas, Petros Christopoulos, Holger Sueltmann
Summary: This study demonstrates the potential of DNA methylation biomarkers in prognosis and therapy monitoring of ALK-positive NSCLC patients. The research highlights the suitability of cfDNA methylation as a non-invasive biomarker for tumor detection and its correlation with other genomic alterations.
CLINICAL EPIGENETICS
(2022)
Article
Oncology
Giuseppe Giaccone, Yongfeng He
Summary: Lung cancer is the leading cause of cancer related death, with two major histological subtypes, NSCLC and SCLC. Transformation from NSCLC to SCLC can cause treatment resistance, potentially due to therapy-induced changes or clonal selection. This article discusses the potential mechanisms, cell of origin, and genomic alterations in both de novo and transformed SCLC, as well as treatment options including chemotherapy, radiotherapy, TKIs, immunotherapy, and antiangiogenic agents.
SEMINARS IN CANCER BIOLOGY
(2023)
Article
Medicine, General & Internal
John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest
Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Isa Mambetsariev, Leonidas Arvanitis, Jeremy Fricke, Rebecca Pharaon, Angel R. Baroz, Michelle Afkhami, Marianna Koczywas, Erminia Massarelli, Ravi Salgia
Summary: EGFR-mutated lung adenocarcinoma patients can transform into SCLC after receiving TKI therapy. This study evaluated 9 patients who underwent such transformation and found that they had unique clinical, molecular, and histological characteristics at different time points. The findings are important for understanding the molecular heterogeneity and clinical outcomes of this EGFR TKI resistance subtype.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Medicine, General & Internal
Yimin Wang, Chuling Li, Zimu Wang, Zhaofeng Wang, Ranpu Wu, Ying Wu, Yong Song, Hongbing Liu
Summary: This systematic review evaluated the efficacy and safety of immunotherapy in early and late lung cancer, finding that immunotherapy has better efficacy in early lung cancer compared to advanced lung cancer, especially when combined with chemotherapy. In terms of safety, immunotherapy, either alone or in combination with other therapies, was found to be safer in early lung cancer than in advanced lung cancer.
Article
Multidisciplinary Sciences
Nathan Farrokhian, Jeff Maltas, Mina Dinh, Arda Durmaz, Patrick Ellsworth, Masahiro Hitomi, Erin McClure, Andriy Marusyk, Artem Kaznatcheev, Jacob G. Scott
Summary: In this study, the frequency-dependent interactions between a gefitinib-resistant non-small cell lung cancer population and its sensitive ancestor were measured experimentally. The cost of resistance was found to be insufficient in predicting competitive exclusion, and frequency-dependent growth rate measurements were necessary. Simulations showed that ecological growth effects can influence the predicted extinction time.
Review
Oncology
Alisa N. Blumenthaler, Mara B. Antonoff
Summary: Around half of NSCLC patients have metastatic disease at diagnosis, some with limited metastatic sites termed oligometastasis. Aggressive treatment of oligometastasis has shown improved survival rates, but the lack of a universal definition hinders comparison between studies.
Review
Oncology
Daijiro Harada, Nagio Takigawa
Summary: Retrospective studies support the effectiveness of the strategy of OPD and LAT in treating NSCLC patients with driver mutations, and it is expected to have some effect in patients without driver mutations in certain conditions. After combination therapy of immune checkpoint inhibitors and chemotherapy, LAT with radiotherapy may also have a positive impact.
Article
Oncology
Lara Perryman, Steven G. Gray
Summary: This article discusses the role of fibrosis in difficult-to-treat cancers and the association of the lysyl oxidase family with fibrosis. It also explores the potential therapeutic effects of drugs targeting lysyl oxidases in the treatment and management of mesothelioma.
Article
Immunology
Arutha Kulasinghe, Ning Liu, Chin Wee Tan, James Monkman, Jane E. Sinclair, Dharmesh D. Bhuva, David Godbolt, Liuliu Pan, Andy Nam, Habib Sadeghirad, Kei Sato, Gianluigi Li Bassi, Ken O'Byrne, Camila Hartmann, Anna Flavia Ribeiro Dos Santos Miggiolaro, Gustavo Lenci Marques, Lidia Zytynski Moura, Derek Richard, Mark Adams, Lucia de Noronha, Cristina Pellegrino Baena, Jacky Y. Suen, Rakesh Arora, Gabrielle T. Belz, Kirsty R. Short, Melissa J. Davis, Fernando Souza-Fonseca Guimaraes, John F. Fraser
Summary: The study reveals distinct transcriptomic profiles in cardiac tissues of SARS-CoV-2 and pH1N1 influenza infection, with upregulation of genes associated with DNA damage and repair, heat shock, and macrophage infiltration in COVID-19 patients' cardiac tissues. In comparison, pH1N1 infection showed upregulation of interferon and complement pathways. This highlights the need for further understanding of the effects on extra-pulmonary organs, including the cardiovascular system, in COVID-19 patients.
Article
Biochemistry & Molecular Biology
Tabassum Khair Barbhuiya, Mark Fisher, Eric D. Boittier, Emma Bolderson, Kenneth J. O'Byrne, Derek J. Richard, Mark Nathaniel Adams, Neha S. Gandhi
Summary: The study investigates the mechanism of CDCA3 binding to APC/C-Cdh1 through the non-canonical ABBA-like motif. The research finds that H-bonds, hydrophobic and ionic interactions within the ABBA-like motif are crucial for the binding. Alanine mutations disrupt the structure of the linker region, leading to altered affinities and binding to alternate sites on Cdh1.
Editorial Material
Oncology
John Hallick, Anne-Marie Baird, Gerald Falchook, Xiuning Le, David Hong, Santiago Viteri, Jo Raskin, Niels Reinmuth, Soetkin Vlassak, Mihaela Militaru, Paul K. Paik
Summary: This article summarizes two main clinical studies that led to the approval of tepotinib. Tepotinib is an orally targeted anti-cancer treatment for advanced or metastatic non-small cell lung cancer (NSCLC) with the genetic mutation MET exon 14 skipping. Targeting this mutation is an important treatment approach to inhibit tumor growth.
Article
Oncology
Lecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer, Wu-Chou Su, Jaafar Bennouna, Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schuler
Summary: The study compared the efficacy of chemotherapy with afatinib in the treatment of EGFR-mutated lung adenocarcinoma. Results showed that afatinib prolonged progression-free survival and improved the quality of life for patients, when compared with chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Mark N. Adams, Laura V. Croft, Aaron Urquhart, Mohamed Ashick Mohamed Saleem, Anja Rockstroh, Pascal H. G. Duijf, Patrick B. Thomas, Genevieve P. Ferguson, Idris Mohd Najib, Esha T. T. Shah, Emma Bolderson, Shivashankar Nagaraj, Elizabeth D. Williams, Colleen C. Nelson, Kenneth J. O'Byrne, Derek J. Richard
Summary: This study evaluated the role of hSSB1/NABP2 in modulating the cellular response to androgens and ionizing radiation in prostate cancer. The expression of hSSB1 in prostate cancer is correlated with genomic instability and it regulates pathways involved in cell cycle progression and transcription. Additionally, hSSB1 is involved in modulating androgen response through transcriptional regulation. Exploiting hSSB1 in prostate cancer treatment might improve patient outcomes in ADT and/or radiotherapy.
Article
Oncology
Grainne Sheill, Lauren Brady, Brian Hayes, Anne-Marie Baird, Emer Guinan, Rishabh Vishwakarma, Caroline Brophy, Tatjana Vlajnic, Orla Casey, Verena Murphy, John Greene, Emma Allott, Juliette Hussey, Fidelma Cahill, Mieke Van Hemelrijck, Nicola Peat, Lorelei Mucci, Moya Cunningham, Liam Grogan, Thomas Lynch, Rustom P. Manecksha, John McCaffrey, Dearbhaile O'Donnell, Orla Sheils, John O'Leary, Sarah Rudman, Ray McDermott, Stephen Finn
Summary: This paper examines the impact of a 6-month aerobic exercise intervention on secondary endpoints in men with metastatic prostate cancer. The results show that the intervention did not lead to changes in quality of life for patients with a high burden of metastatic disease. Further research is needed to understand the role of exercise for people living with metastatic prostate cancer.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Medicine, General & Internal
Sanna Iivanainen, Anne-Marie Baird, Bogdana Balas, Alberto Bustillos, Amparo Yovanna Castro Sanchez, Manuela Eicher, Sophie Golding, Mathis Mueller-Ohldach, Maria Reig, Manfred Welslau, Johannes Ammann
Summary: ORIGAMA is an interventional, multicountry platform study to investigate the clinical utility of digital patient monitoring (DPM) tools and specific treatments. It aims to assess the impact of the atezolizumab-specific Roche DPM Module on health outcomes and healthcare resource usage, and its feasibility to support at-home treatment administration. Other digital health solutions may be included in future cohorts.
Article
Oncology
Ming Tang, Joshua T. Burgess, Mark Fisher, Didier Boucher, Emma Bolderson, Neha S. Gandhi, Kenneth J. O'Byrne, Derek J. Richard, Amila Suraweera
Summary: This study aimed to explore the binding pose of COMMD4-H2B and develop a H2B peptide that disrupts the COMMD4-H2B interaction, which could serve as a potential therapeutic target for non-small cell lung cancer (NSCLC).
BRITISH JOURNAL OF CANCER
(2023)
Editorial Material
Oncology
Rachel J. Keogh, Martin P. Barr, Anna Keogh, David McMahon, Anne-Marie Baird, Seamus Cotter, David Breen, Gerard J. Fitzmaurice, David Fitzpatrick, Cathal O'Brien, Stephen P. Finn, Jarushka Naidoo
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Sugandha Bhatia, Jennifer H. Gunter, Joshua Burgess, Mark N. Adams, Kenneth O'Byrne, Erik W. Thompson, Pascal H. G. Duijf
Summary: Epithelial-mesenchymal plasticity (EMP) is a characteristic of cancer that promotes invasion, metastasis, and therapy resistance. This study shows that non-cancerous human epithelial lung cells can spontaneously shift towards a mesenchymal-like state without genetic changes. This suggests that acquisition of metastasis-associated features may occur prior to genetic alterations and cancerous transformation.
TRANSLATIONAL ONCOLOGY
(2023)
Article
Biology
Zachariah P. Schuurs, Alexander P. Martyn, Carl P. Soltau, Sam Beard, Esha T. Shah, Mark N. Adams, Laura V. Croft, Kenneth J. O'Byrne, Derek J. Richard, Neha S. Gandhi
Summary: This study explores small molecules that bind to hSSB1, an important protein related to the survival of cancer cells. Through computational and experimental approaches, three small molecules were discovered that prevent hSSB1 from binding to DNA, potentially interfering with the cell's ability to repair DNA. Further research is needed to understand the interaction between these compounds and cells, and to develop them as selective hSSB1 inhibitors.
Article
Oncology
Mark Lawler, Lynne Davis, Simon Oberst, Kathy Oliver, Alexander Eggermont, Anna Schmutz, Carlo La Vecchia, Claudia Allemani, Yolande Lievens, Peter Naredi, Tanja Cufer, Ajay Aggarwal, Matti Aapro, Kathi Apostolidis, Anne-Marie Baird, Fatima Cardoso, Andreas Charalambous, Michel P. Coleman, Alberto Costa, Mirjam Crul, Csaba L. Degi, Federica Di Nicolantonio, Sema Erdem, Marius Geanta, Jan Geissler, Jacek Jassem, Beata Jagielska, Bengt Jonsson, Daniel Kelly, Olaf Kelm, Teodora Kolarova, Tezer Kutluk, Grant Lewison, Francoise Meunier, Jana Pelouchova, Thierry Philip, Richard Price, Beate Rau, Isabel T. Rubio, Peter Selby, Maja Juznic Sotlar, Gilliosa Spurrier-Bernard, Jolanda C. van Hoeve, Eduard Vrdoljak, Willien Westerhuis, Urszula Wojciechowska, Richard Sullivan
Summary: Cancer research is vital for improving cancer care, and patients treated in research-active hospitals have better outcomes. However, the COVID-19 pandemic has negatively impacted cancer outcomes in Europe and set back progress by almost a decade. The Lancet Oncology European Groundshot Commission aims to use detailed data on cancer research to inform future cancer care strategies in Europe.
Article
Chemistry, Physical
Ming Tang, Amila Suraweera, Xuqiang Nie, Zilin Li, Pinglin Lai, James W. Wells, Kenneth J. O'Byrne, Robert J. Woods, Emma Bolderson, Derek J. Richard
Summary: In this study, the atomic-level mechanisms of Banf1-DNA binding and the effects of mono- and di-phosphorylation on Banf1's DNA-binding capability were explored using molecular modelling and dynamics simulations. It was found that mono-phosphorylation induces changes in Banf1's secondary structure, leading to the elimination of its DNA-binding capability. The study also demonstrated that phosphorylated Banf1 binds to DNA with lower affinity and less stable binding poses. These findings have implications for predicting the effects of Banf1 mutations on its DNA-binding capability and potential development of therapeutic drugs targeting cell proliferation.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS
(2023)
Article
Multidisciplinary Sciences
Thais Sobanski, Amila Suraweera, Joshua T. Burgess, Iain Richard, Chee Man Cheong, Keyur Dave, Maddison Rose, Mark N. Adams, Kenneth J. O'Byrne, Derek J. Richard, Emma Bolderson
Summary: This study reveals that the glycolytic protein ALDOA plays a direct role in DNA double-strand break (DSB) repair. Upon DNA damage, ALDOA translocates into the nucleus and associates with the DNA DSB marker γ-H2AX. Depletion of ALDOA leads to increased DNA damage before and slower repair after ionising radiation. It is suggested that targeting ALDOA may be a potential strategy for simultaneous disruption of cancer metabolism and DNA repair.
SCIENTIFIC REPORTS
(2023)
